Free Trial

Indivior (LON:INDV) Stock Price Down 15.7% - Here's Why

Indivior logo with Medical background

Indivior PLC (LON:INDV - Get Free Report) shares traded down 15.7% during trading on Thursday . The company traded as low as GBX 548.71 ($6.95) and last traded at GBX 732 ($9.28). 1,888,371 shares changed hands during mid-day trading, an increase of 166% from the average session volume of 709,477 shares. The stock had previously closed at GBX 868 ($11.00).

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group reaffirmed a "buy" rating and set a GBX 1,800 ($22.81) target price on shares of Indivior in a research report on Tuesday, December 17th.

View Our Latest Analysis on INDV

Indivior Stock Performance

The company has a market capitalization of £1.14 billion, a P/E ratio of -606.93, a price-to-earnings-growth ratio of -5.57 and a beta of 0.19. The firm has a 50 day moving average price of GBX 924.76 and a two-hundred day moving average price of GBX 852.88. The company has a debt-to-equity ratio of -170.06, a quick ratio of 1.52 and a current ratio of 0.83.

Indivior Company Profile

(Get Free Report)

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Indivior Right Now?

Before you consider Indivior, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.

While Indivior currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines